At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 41 enrolled

Drug / intervention

Zanubrutinib +1 moredrug

Likely dose

Zanubrutinib 160 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03520920

NCT03520920Phase 2Completed

Compare CT.gov

A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

BeiGene·interventional·Posted May 11, 2018·Updated Oct 26, 2024

In Brief

A Phase 2 clinical trial evaluating Zanubrutinib and Rituximab for Marginal Zone Lymphoma and 2 related conditions. Completed, enrolled 41 participants across 4 sites.

Detailed Summary

This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (non-GCB \[non-germinal center B-cell-like\] subtype) and R/R indolent lymphoma (follicular lymphoma \[FL\] and marginal zone lymphoma \[MZL\]).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMarginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma

CountriesChina

Collaborators--

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

Enrollment StartJan 2018

First PostedMay 2018

Primary CompletionAug 2020

TodayJul 2026

First PostedMay 11, 2018

Enrollment StartJan 4, 2018

Primary CompletionAug 28, 2020

TodayJul 2, 2026

Enrollment to primary: 2.6 yearsPosted 8.1 years ago

Interventions

Zanubrutinibdrug

Administered zanubrutinib 160 mg orally (PO) BID continuously

Rituximabdrug

Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.